<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632019</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2015-02-006</org_study_id>
    <nct_id>NCT02632019</nct_id>
  </id_info>
  <brief_title>Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract</brief_title>
  <official_title>A Clinical Study of Adoptive Cellular Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen in Treating Patients With Advanced Malignant Tumor of Biliary Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Military Medical University</source>
  <brief_summary>
    <textblock>
      Objectives:

      The purpose of this study is to evaluate the safety and prognosis of dendritic cell-precision
      T cell for neo-antigen in the treatment of advanced biliary tract malignant tumor.

      Methods:

      This study designs a novel therapy using dendritic cell-precision multiple antigen T cells.
      40 patients will be enrolled. They are randomly divided into gemcitabine group and dendritic
      cell-precision T cell for neo-antigen combined with gemcitabine group. Gemcitabine treatments
      will be performed once a week with a total of six times. Dendritic cell-precision T cell for
      neo-antigen combined with gemcitabine treatment: Gemcitabine: once a week with a total of six
      times before 60 days prior to the start of drawing blood. Dendritic cell-precision T cell for
      neo-antigen: once per 3 weeks with a total of three periods. The mail clinical indicators are
      Progression-Free-Survival and Overall Survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 40 patients may be enrolled over a period of 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 yeas</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>2 yeas</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 yeas</time_frame>
    <description>Quality of life core questionnaire will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Biliary Tract Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine treatments will be performed once a week with a total of six times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dendritic cell-precision T cell for neo-antigen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.</description>
    <arm_group_label>gemcitabine</arm_group_label>
    <arm_group_label>Dendritic cell-precision T cell for neo-antigen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment</intervention_name>
    <description>Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.</description>
    <arm_group_label>Dendritic cell-precision T cell for neo-antigen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 18~65 years old, male or female;2. Life expectancy ＞ 6 months;3. Eastern
             Cooperative Oncology Group (ECOG) score: 0-2;4. Laboratory examination: ① white blood
             cell ≥ 3 x 109/L. blood platelet count ≥ 60 x 109/L; hemoglobin ≥85g/L; ② total
             bilirubin ≤100 mol/L; aminopherase less than five times of the normal; ③ serum
             creatinine less than 1.5 times of the normal;5. Signed informed consent;6. Patients
             with fertility are willing to use contraceptive method.

        Exclusion Criteria:

          -  1. Expected Overall survival ＜ 6 months;2.Other serious diseases:the heart,lung,
             kidney, digestive, nervous, mental disorders, immune regulatory diseases, metabolic
             diseases, infectious diseases, Etc.3.serum creatinine &gt; 2.5mg/dL; Serum Glutamic
             Oxaloacetic Transaminase (SGOT) &gt; 5 times of the normal;total bilirubin &gt; 100μmol/L;
             4.Other drugs, biological, chemotherapy or radiation therapy were used within 1
             months;5. Without signed Informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoqing Jiang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qijun Qian, PHD</last_name>
    <phone>+86-21-65580677</phone>
    <email>qianqj@sino-gene.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huajun Jin, PHD</last_name>
    <phone>+86-21-81875372</phone>
    <email>hj-jin@Hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huajun Jin, PHD</last_name>
      <phone>+86-21-81875372</phone>
      <email>hj-jin@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoqing Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qijun Qian, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huajun Jin, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiangji Luo, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinghan Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chang Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxia Kou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Review.</citation>
    <PMID>24140396</PMID>
  </reference>
  <reference>
    <citation>Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32. doi: 10.1016/j.bpg.2015.02.003. Epub 2015 Feb 16. Review.</citation>
    <PMID>25966423</PMID>
  </reference>
  <reference>
    <citation>Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006 May;132(5):293-301. Epub 2006 Jan 19.</citation>
    <PMID>16421755</PMID>
  </reference>
  <reference>
    <citation>Knippertz I, Hesse A, Schunder T, Kämpgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun;32(5):524-38. doi: 10.1097/CJI.0b013e3181a28422.</citation>
    <PMID>19609245</PMID>
  </reference>
  <reference>
    <citation>Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.</citation>
    <PMID>19417017</PMID>
  </reference>
  <reference>
    <citation>Bellik L, Gerlini G, Parenti A, Ledda F, Pimpinelli N, Neri B, Pantalone D. Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol. 2006 Oct;121(1):74-80. Epub 2006 Aug 17.</citation>
    <PMID>16914380</PMID>
  </reference>
  <reference>
    <citation>Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006 Mar;55(3):268-76. Epub 2005 Jul 21.</citation>
    <PMID>16034561</PMID>
  </reference>
  <reference>
    <citation>Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, Ueno H, Banchereau J. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006 Oct;55(10):1209-18. Epub 2005 Dec 6.</citation>
    <PMID>16331519</PMID>
  </reference>
  <reference>
    <citation>Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother. 2006 Sep-Oct;29(5):499-511.</citation>
    <PMID>16971806</PMID>
  </reference>
  <reference>
    <citation>Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005 Dec;142(3):555-68.</citation>
    <PMID>16297169</PMID>
  </reference>
  <reference>
    <citation>Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006 Nov 15;119(10):2428-34.</citation>
    <PMID>16977630</PMID>
  </reference>
  <reference>
    <citation>Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate. 2006 Jun 1;66(8):811-21.</citation>
    <PMID>16482569</PMID>
  </reference>
  <reference>
    <citation>Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2006 Nov;55(11):1432-42. Epub 2006 Apr 13. Review.</citation>
    <PMID>16612595</PMID>
  </reference>
  <reference>
    <citation>Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother. 2005 Nov-Dec;28(6):551-9.</citation>
    <PMID>16224272</PMID>
  </reference>
  <reference>
    <citation>Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother. 2005 Jul;54(7):663-70. Epub 2004 Dec 17.</citation>
    <PMID>15918076</PMID>
  </reference>
  <reference>
    <citation>Ferrari S, Malugani F, Rovati B, Porta C, Riccardi A, Danova M. Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. Oncol Rep. 2005 Jul;14(1):113-20.</citation>
    <PMID>15944777</PMID>
  </reference>
  <reference>
    <citation>Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol. 2004 Sep-Oct;231(1-2):112-25. Epub 2005 Feb 8.</citation>
    <PMID>15919376</PMID>
  </reference>
  <reference>
    <citation>Chen W, Chan AS, Dawson AJ, Liang X, Blazar BR, Miller JS. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol Blood Marrow Transplant. 2005 Jan;11(1):23-34.</citation>
    <PMID>15625541</PMID>
  </reference>
  <reference>
    <citation>Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000 Dec 15;89(12):2646-54.</citation>
    <PMID>11135227</PMID>
  </reference>
  <reference>
    <citation>Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.</citation>
    <PMID>25428503</PMID>
  </reference>
  <reference>
    <citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.</citation>
    <PMID>25428505</PMID>
  </reference>
  <reference>
    <citation>Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.</citation>
    <PMID>25428507</PMID>
  </reference>
  <reference>
    <citation>Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.</citation>
    <PMID>25428506</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.</citation>
    <PMID>25428504</PMID>
  </reference>
  <reference>
    <citation>Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172. Review.</citation>
    <PMID>25838373</PMID>
  </reference>
  <reference>
    <citation>Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013 Apr 3;5(179):179ps7. doi: 10.1126/scitranslmed.3005568.</citation>
    <PMID>23552369</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967. Review.</citation>
    <PMID>25838374</PMID>
  </reference>
  <reference>
    <citation>Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69-74. doi: 10.1126/science.aaa4971. Review.</citation>
    <PMID>25838375</PMID>
  </reference>
  <reference>
    <citation>Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.</citation>
    <PMID>23644516</PMID>
  </reference>
  <reference>
    <citation>Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.</citation>
    <PMID>24812403</PMID>
  </reference>
  <reference>
    <citation>Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010 Jun;22(3):333-40. doi: 10.1016/j.coi.2010.02.013. Epub 2010 Apr 2. Review.</citation>
    <PMID>20363604</PMID>
  </reference>
  <reference>
    <citation>Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974 Apr 19;248(5450):701-2.</citation>
    <PMID>4133807</PMID>
  </reference>
  <reference>
    <citation>Lafferty KJ, Warren HS, Woolnough JA. A mediator acting as a costimulator for the development of cytotoxic responses in vitro. Adv Exp Med Biol. 1979;114:497-501.</citation>
    <PMID>313677</PMID>
  </reference>
  <reference>
    <citation>Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 2012 Oct;24(5):633-9. doi: 10.1016/j.coi.2012.06.004. Epub 2012 Jul 18. Review.</citation>
    <PMID>22818942</PMID>
  </reference>
  <reference>
    <citation>Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126-9. Epub 2006 Aug 31.</citation>
    <PMID>16946036</PMID>
  </reference>
  <reference>
    <citation>Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med. 2015 Jun;12(2):74-8. doi: 10.7497/j.issn.2095-3941.2015.0022.</citation>
    <PMID>26175922</PMID>
  </reference>
  <reference>
    <citation>Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008 Apr 15;68(8):2561-3. doi: 10.1158/0008-5472.CAN-07-6229. Review.</citation>
    <PMID>18413722</PMID>
  </reference>
  <reference>
    <citation>Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83.</citation>
    <PMID>9448305</PMID>
  </reference>
  <reference>
    <citation>Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208. Review.</citation>
    <PMID>16551247</PMID>
  </reference>
  <reference>
    <citation>Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun;5(6):677-85.</citation>
    <PMID>10371507</PMID>
  </reference>
  <reference>
    <citation>Radoja S, Saio M, Frey AB. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol. 2001 May 15;166(10):6074-83.</citation>
    <PMID>11342625</PMID>
  </reference>
  <reference>
    <citation>Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol. 2001 Nov 1;167(9):5042-51.</citation>
    <PMID>11673513</PMID>
  </reference>
  <reference>
    <citation>Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May;229(1):126-44. doi: 10.1111/j.1600-065X.2009.00771.x. Review.</citation>
    <PMID>19426219</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced biliary tract malignant tumor</keyword>
  <keyword>dendritic cell</keyword>
  <keyword>precision T cell for neo-antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

